

Acute and subacute toxicity of *Oxalis barrelieri* (Oxalidaceae) aqueous aerial parts extract

ABSTRACT

Aims: The present study was carried out to investigate the toxic effects of the *Oxalis barrelieri* aqueous aerial parts extract.

Place and Duration of Study: Department of Biological Sciences (Animal Physiology Laboratory), Higher Teachers' Training College, University of Yaoundé I. Between April 2017 and June 2018.

Materials and methods: Acute toxicity using a single dose of 2000 mg/kg was administered to mice and effects were observed for 14 days. In sub-acute toxicity, the experimental rats (males and females) received aqueous extract of *Oxalis barrelieri* at doses of 200 mg/kg, 400 mg/kg and 800 mg/kg daily for 28 days while the control and satellite control groups received distilled water and satellite test group received extract at the dose of 800 mg/kg. The physical parameters were evaluated throughout the treatment, while the haematological, biochemical and histological parameters were evaluated at the end of the treatment.

Results: In acute toxicity, the results obtained show no death and no significant variation ($p > 0.05$) in behavioral and morphological parameters. In sub-acute toxicity assay, few modifications were observed in haematological and biochemical parameters. At the higher dose of extract (800 mg/kg), the rate of red blood cells decreased significantly ($p < 0.05$) two weeks after treatment in male rats, there were a significant increase ($P < 0.001$) in ASAT activity in male and female rats two weeks after extract administration, and a reversible significant increase ($P < 0.05$) in triglyceride level in male rats only. Histopathology showed a reversible slight dose dependent structural alteration of the kidney and reversible vascular congestion in liver.

Conclusion: The aqueous aerial parts extract of *Oxalis barrelieri* could possess moderate toxicity at high doses and adequate caution should be exercised in its use in ethnomedicine.

Keywords: *Oxalis barrelieri*, aqueous extract, acute toxicity, sub-acute toxicity, Oxalidaceae.

1. INTRODUCTION

Oxalis is a cosmopolitan genus of more than 800 species, but major centers of diversity are in South America and South Africa. *Oxalis barrelieri* (synonym: *O. sepium*) is native to tropical South America, but has naturalized in many areas. It was first observed in Java in 1888. In South-East Asia it is common in Indonesia (Sumatra, Bangka, Java, Irian Jaya), Peninsular Malaysia, and Papua New Guinea [1]. *Oxalis barrelieri* is a ruderal, annual upright herb up to 60 cm tall found on sandy, acid soils [2]. *O. barrelieri* is a highly nectariferous and highly pollinating apiculture plant [3]. Leaves subopposite, pinnately 3-foliolate, without stipules; petiole 2-9 cm long, canaliculate, ascendent; petiolule fleshy, about 1 mm long; leaflet elliptical to oblong, 1-5.5 cm x 0.5-2.5 cm, terminal one largest, base cuneate to emarginate, margin ciliate (especially at base), apex obtuse to rounded, discolorous, glaucous above. Inflorescence cymose, up to 30-flowered; peduncle up to 6.5 cm long, bifid with branches up to 3 cm long, pubescent; bracts opposite the pedicels, pilose; pedicel up to 3 mm long with appressed bracteoles; sepals ovate lanceolate, 2-4 mm x 0.5-1.5 mm, light green, sometimes reddish veined; petals obovate-lanceolate, 6-9 mm x 2-2.5 mm, pink but lower half greenish with yellow spots, rolling inwards after anthesis; outer stamens up to 2 mm long, inner ones up to 3 mm long bearing a dorsal tooth; pistil 3.5-4 mm long, carpels 3-4-ovuled, styles 1-1.5 mm long, pubescent. Capsule ovoid, 5-10 mm x 3-5 mm, 5-angular, base and apex 5-lobed, glabrous. Seeds

48 usually 3 per carpel flatten edovoid, about 1.5-2 mm x 1 mm, 8-ribbed in zigzag, deeply transversely
49 striate, brownish [1,4]. *O. barrelieri* is known as “belimbing tanah” in Malaysia, as “Tetele owono
50 bekon” in South Cameroon. *O. barrelieri* has been claimed to have effect on antifungal and free radical
51 scavenging activities [5]. Enoch et al. [6] reported that administration of 500 mg/kg and 1000 mg/kg
52 aqueous and ethanolic extracts of *O. barrelieri* on Sprague-dawley rats produced significant
53 reductions of glycemia in both non-diabetic and diabetic rats. A decoction of the entire plant is used for
54 the treatment of diarrhea [7, 8]. *O. barrelieri* is rich in phenols, flavonoïds, tannins, alkaloids and
55 saponins [9]. However, the toxicity of *Oxalis barrelieri* has not been intensively studied in order to
56 ascertain the limits of it application. The aim of this study was to investigate the acute and sub-acute
57 toxicity effects of the aqueous aerial parts extract of this plant.

58 **2. MATERIALS AND METHODS**

59

60 **2.1 Plant Collection, Identification and Extract Preparation**

61 The leaves of *Oxalis barrelieri* were harvested in April 2017 at Yaoundé, in the Center Region
62 of Cameroon. Botanical identification was done in the National Herbarium, Yaounde, by Paul MEZILI,
63 by comparing with existing herbarium specimen no. 24509. The aerial parts of *Oxalis barrelieri* were
64 dried at room temperature. The dried ground aerial parts of *Oxalis barrelieri* were extracted in distilled
65 water by boiling 168 g in 4.18 L of water for 15 minutes and the extract solution was filtered using
66 Wattman filter paper no 3. The filtrate was lyophilized and the resulting solid was used for the toxicity
67 tests. The resulting material weighed 34.44 g, giving a percentage yield of 20.52% with respect to the
68 powder. The extract re-dissolved readily in distilled water which was used as the vehicle.

69

70 **2.2 Experimental animals**

71 Female Swiss mice weighing 23 ± 3 g (10 ± 2 weeks) were used for acute toxicity ,and male
72 and female young Wistar rats weighing 78 -120 g (6 to 8 weeks) for sub acute toxicity. These animals
73 were raised in the Animal house of the Higher Teachers' Training College, University of Yaoundé I.
74 They were fed a standard laboratory diet (NAAPCAM Sarl, Yaoundé, Cameroon) and given fresh
75 water *ad libitum*. Before the experiments (acute toxicity), they were starved for 12 h in wire mesh
76 bottom cages to prevent coprophagy but allowed free access to water. Prior authorization for the use
77 of Laboratory Animals was obtained from the Cameroon National Ethics Committee (Reg. N°
78 FWAIRB00001954). The use, handling and care of animals were done in adherence to the European
79 Convention (Strasbourg, 18.III.1986) for the protection of vertebrate animals used for experimental
80 and other purposes (ETS-123), with particular attention to Part III, articles 7, 8 and 9.

81 **2.3 Acute toxicity**

82 The acute toxicity was performed according to the sequential method of OECD (Organization
83 for Economic Co-operation and Development). Using a stomach tube, the *O. barrelieri* extract was
84 administered to three female mice (20 – 26g) with a single dose (2000 mg / kg). The control group
85 received vehicle. The same method and the same dose were repeated 48 hours later, on 3 additional
86 animals. Thereafter, all animals were observed carefully for 14 days during which mortality, body
87 weights and gross behavioral change were noted daily [10].

88 **2.4 Sub acute toxicity**

89 Young Wistar rats (78-120 g) in six groups of 12 animals (6 males and 6 females) for each
90 dose level of *Oxalis barrelieri* were used in these tests. Sub acute toxicity was evaluated after single
91 daily administration of extract at 200, 400 and 800 mg / kg orally for a period of 4 weeks. The satellite
92 group was also treated with the extract of *Oxalis barrelieri* (800 mg/kg) for 4 weeks but these animals
93 were sacrificed 2 weeks after stopping treatment. The satellite control and control group received
94 vehicle. Satellite control was sacrificed 2 weeks after treatment. All rats were maintained under
95 identical conditions with food and water *ad libitum* for the entire period with close observation. Toxicity
96 was evaluated in terms of corporal and organ weights (heart, kidney, liver, spleen, lungs, ovaries and
97 testicles), gross behavior, gross and histological appearance of detoxification organs (kidney and
98 liver). The plasma from EDTA blood prepared was carefully collected for blood chemistry and enzyme
99 analysis (total protein, AST, ALT, creatinine, urea, total cholesterols and triglycerides) using
100 Commercial kits (Fortress) and glycaemia using a glucometer (One Touch Ultra). The Haematological
101 parameters (white blood cell count, red blood cell count, platelet count, hemoglobin, haematocrit,
102 Medium Globular Volume (MGV), Average Corpuscle Concentration in Hemoglobin(ACCH), Average
103 Volume of Platelets (AVP), Thrombocrits (THT), Average Corpuscle Content in Hemoglobin (ACCh)
104 and Red Blood Cell Distribution Index (RDI) were evaluated using a Coulter counter [10,11,12].

105
106

107 2.5 Statistical analysis

108 The results were reported as mean \pm SEM. The statistical significance was determined by
109 using one way analysis of variance (ANOVA) followed by Tukey multiple comparison tests. P values
110 less than 0.05 were considered as significant.

111 3. RESULTS

112 3.1 Acute toxicity

113 Administration of a single dose of aqueous extract of *Oxalis barrelieri* (2000 mg/kg) in mice did
114 not result in any deaths in the first stage. 48 hours later, carrying out a second test did not result in any
115 deaths. After 14 days of observation, no changes were observed in mice regarding: coat color,
116 appearance, saddles, reflexes, alertness, heart rate, respiratory rate, sensitivity to noise, sensitivity to
117 touch and body weight (Tables 1 and 2). The aqueous extract of *Oxalis barrelieri* is classified in
118 category 5 which includes substances with LD₅₀ is greater than 2000 mg/kg, according to OECD
119 guideline 423, 2001.

120

121

122

123

124

125

126

127

128

129 **Table 1. Behavioral parameters observed in mice treated with *O. barrelieri* aqueous extract**

130

Treatment	Sex	Convulsions	Reactions weird	Agressivity	pilo-erection	sensitivity noise	sensitivity touch	Change coat	Number of deaths	Stool appearance
Distilled water	Female 1	-	-	-	-	+	+	-	-	Normal
	Female 2	-	-	-	-	+	+	-	-	Normal
	Femelle 3	-	-	-	-	+	+	-	-	Normal
O.b 2000 mg/kg	Femelle 1	-	-	-	-	+	+	-	-	Normal
	Femelle 2	-	-	-	-	+	+	-	-	Normal
	Femelle 3	-	-	-	-	+	+	-	-	Normal

131 -Parameter absent; + Parameter present (Each group contains 3 females)

132
133

134 Mice given the single dose of *O. barrelieri* aqueous extract showed non significant and non-
135 dose-dependent changes in body weight (Table 2).
136

137 **Table 2. Body weight change of mice during acute toxicity study of *Oxalis barrelieri***
138 **aqueous extract**

139

Weight	Treatment	Distilled water (1 ml/100g)	<i>Oxalis barrelieri</i> extract	
			Test group	Confirmation group
Initial weight(g)		21.00±1.11	22.67±1.33	22.35±3.18
Final weight (g)		23.67±0.87	25.33±0.88	25.33±2.40
Body weight variation (%)		+12.71	+11.73	+13.33

140 *n* = 3 animals in each group; Values are expressed as mean ± SEM

141 3.2 Sub acute toxicity

142 All rats (male and female) treated with *O. barrelieri* extract showed a body weight gain
143 similar to that of control rats. No loss of body weight was observed. Male rats had higher weight gain
144 than female rats (Tables 3 and 4).
145

146 **Table3. Body weight change of male rats during sub acute toxicity study of *Oxalis barrelieri***
147 **aqueous extract**

148

Groups	Weight body variation of male rats (%).					
	7 th day	14 th day	21 st day	28 th day	35 th day	42 th day
Control	+29,45	+46,16	+77,57	+83,36		
<i>O.b.</i> 200mg/kg	+30,19	+57,39	+60,17	+70,30		
<i>O.b.</i> 400mg/kg	+20,99	+31,08	+51,33	+64,37		
<i>O.b.</i> 800mg/kg	+22,91	+40,03	+64,49	+73,24		
Satellite test	+18,22	+46,48	+67,05	+72,42	+100,64	+113,13
Satellite control	+25,71	+43,55	+56,67	+69,07	+92,70	+107,83

149 *n* = 5 animals in each group; Values are expressed as mean ± SEM

150
151
152

153 **Table 4. Body weight change of female rats during sub acute toxicity study of *Oxalis barrelieri***
 154 **aqueous extract**

Weight body variation of female rats (%).						
Groups	7 th day	14 th day	21 st day	28 th day	35 th day	42 th day
Control	+24,71	+37,22	+55,13	+63,55		
<i>O.b.</i> 200mg/kg	+19,01	+29,41	+50,30	+60,22		
<i>O.b.</i> 400mg/kg	+11,69	+27,25	+40,37	+54,41		
<i>O.b.</i> 800mg/kg	+16,85	+33,76	+51,92	+64,11		
Satellite test	+18,30	+37,79	+49,50	+56,40	+72,55	+71,12
Satellite control	+20,45	+34,65	+48,99	+61,28	+74,30	+80,05

156 *n* = 5 animals in each group; Values are expressed as mean ± SEM

157 Table 5 shows that *O. barrelieri* extract did not cause any significant variation in vital organs
 158 weight compared to control group, during treatment. However, a significant decrease in spleen weights
 159 was observed in satellite male rats (*p* <0.01). A significant (*p* <0.001) non-dose-dependent increase in
 160 heart weight was observed in male rats treated with the 200 mg / kg extract dose.

161 **Table 5. Effect of the *Oxalis barrelieri* aqueous extract on rat organs weights (values**
 162 **expressed as the percentage of organ weight over the body weight)**

Organs	Control	O. b. 200mg/kg	O. b. 400mg/kg	O. b. 800mg/kg	Satellite test	Sat. C.
Males						
Liver	3.62±0.41	3.15±0.07	3.09±0.07	2.89±0.15	2.81±0.10	2.35±0.21
Right kidney	0.30±0.05	0.35±0.01	0.39±0.07	0.33±0.01	0.34±0.05	0.35±0.03
Left kidney	0.31±0.05	0.34±0.02	0.37±0.05	0.33±0.02	0.33±0.05	0.33±0.02
Lungs	0.81±0.04	0.99±0.07	0.93±0.04	0.82±0.04	0.94±0.21	0.81±0.03
Spleen	0.55±0.05	0.46±0.01	0.45±0.03	0.49±0.03	0.36±0.01**	0.58±0.03
Heart	0.38±0.01	0.51±0.03***	0.46±0.01	0.40±0.02	0.37±0.00	0.39±0.01
Right testicle	0.66±0.04	0.61±0.04	0.59±0.04	0.62±0.02	0.60±0.05	0.71±0.03
Left testicle	0.66±0.05	0.62±0.03	0.61±0.04	0.60±0.03	0.66±0.05	0.70±0.02
Female						
Liver	2.89±0.06	2.87±0.06	2.96±0.14	2.92±0.18	2.85±0.07	3.11±0.08
Right kidney	0.39±0.03	0.40±0.05	0.37±0.04	0.36±0.03	0.37±0.02	0.44±0.04
Left kidney	0.36±0.02	0.38±0.04	0.36±0.03	0.36±0.03	0.39±0.03	0.43±0.04
Lungs	0.75±0.07	0.90±0.11	0.82±0.04	1.01±0.07	0.81±0.07	0.96±0.05
Spleen	0.51±0.07	0.43±0.03	0.56±0.07	0.61±0.09	0.42±0.06	0.49±0.02
Heart	0.39±0.04	0.49±0.03	0.50±0.04	0.44±0.02	0.42±0.03	0.48±0.02
Right ovary	0.05±0.01	0.04±0.00	0.05±0.01	0.06±0.01	0.05±0.00	0.06±0.01
Left ovary	0.06±0.01	0.05±0.01	0.07±0.01	0.07±0.01	0.05±0.01	0.06±0.00

165 *O. b.*: *Oxalis barrelieri* aqueous extract; *Sat. C.*: Satellite control

166 *n* = 5 animals in each group; Values are expressed as mean ± SEM

167 ***p*<0.01: statistically significant compared to control; ****p*<0.001: statistically significant compared to
 168 control

169
 170 *O. barrelieri* extract did not induce any significant dose-dependent variation on the
 171 hematological parameters. However, female rats treated with *O. barrelieri* extract at dose of 200 mg /
 172 kg showed a significant (*p* <0.05) non-dose-dependent increase of red blood cells. In male rats, *O.*
 173 *barrelieri* (800 mg/kg) extract caused significant (*p*<0.05) diminution of red blood cell two weeks after
 174 treatment (Table 6).

175
 176
 177
 178

Table 6. Effect of *Oxalis barrelieri* aqueous extract of on hematological parameters in rat.

Parameters	Control	O.b. 200mg/kg	O.b. 400mg/kg	O.b. 800mg/kg	Satellite test	C. Sat.
Males						
RBC($10^6/\text{mm}^3$)	8.14±0.34	8.07±0.34	6.87±0.29	7.07±0.17	6.44±0.29 *	7.01±0.56
Haematocrit (%)	45.24±3.54	48.34±3.14	37.30±4.03	39.12±7.62	39.50±5.62	42.62±4.48
Haemoglobin(g/dl)	15.30±0.39	16.24±0.76	14.94±0.56	14.76±0.90	15.22±1.25	14.82±0.20
Platelet($10^3/\text{mm}^3$)	672.80±51.12	699.60±23.03	628.80±39.75	614.60±27.54	605.60±15.11	508.60±65.73
WBC ($10^3/\text{mm}^3$)	7.04±0.64	8.72±0.88	7.42±0.74	7.89±1.34	7.82±1.86	7.11±1.35
MGV (fL)	57.80±0.80	62.60±1.03	61.60±0.93	62.60±0.81	60.80±2.13	62.20±0.86
ACCH (g/dL)	29.74±0.66	32.62±2.71	34.64±1.12	32.10±1.69	33.98±2.05	31.82±2.87
VMP (fL)	9.72±0.40	10.16±0.25	8.74±0.27	9.30±0.41	9.98±0.67	9.36±0.39
THT (%)	0.66±0.04	0.69±0.03	0.57±0.04	0.65±0.07	0.62±0.08	0.52±0.09
ACCh (pg)	17.66±0.26	21.90±0.99	21.64±0.96	20.12±1.19	20.90±1.98	19.88±1.51
RDI (%)	13.32±0.49	13.94±0.51	13.20±0.94	13.84±0.76	13.96±0.54	14.52±0.83
Females						
RBC($10^6/\text{mm}^3$)	7.52±0.28	9.44±0.52*	8.03±0.34	8.31±0.23	7.30±0.52	8.05±0.21
Haematocrit (%)	45.16±1.27	57.26±2.59	44.38±6.50	49.44±1.54	43.38±3.83	50.36±1.15
Haemoglobin(g/dl)	13.76±0.39	16.32±1.27	13.92±0.25	14.28±0.47	13.66±1.12	14.42±0.39
Platelet($10^3/\text{mm}^3$)	624.40±43.72	748.40±88.77	818.60±66.49	732.60±29.84	618.00±70.13	554.80±31.81
WBC ($10^3/\text{mm}^3$)	8.31±0.51	7.27±0.46	9.02±0.72	7.83±1.14	7.23±0.12	8.05±0.42
MGV (fL)	59.60±0.87	61.00±1.52	60.80±0.58	59.40±1.69	59.40±2.42	61.60±0.81
ACCH (g/dL)	30.10±1.37	28.36±0.99	27.88±0.76	28.86±0.50	31.76±1.49	29.50±0.35
AVP (fL)	9.80±0.40	9.62±0.35	8.88±0.38	9.60±0.55	9.16±0.52	9.48±0.06
THT (%)	0.55±0.05	0.72±0.06	0.69±0.09	0.70±0.04	0.52±0.09	0.59±0.02
ACCh (pg)	18.88±1.83	17.22±0.61	17.00±0.51	17.18±0.28	18.90±1.50	18.06±0.41
RDI (%)	13.80±0.66	14.84±0.53	14.78±0.00	14.92±0.33	14.28±0.41	13.16±0.35

181 O. b: *Oxalis barrelieri* aqueous extract; Sat. C: Satellite control; n = 5 animals in each group; Values
 182 are expressed as mean ± SEM; *p<0.05: statistically significant compared to control;
 183 ACCH: Average Corpuscle Concentration in Hemoglobin; ACCh: Average Corpuscle Content in
 184 Hemoglobin; MGCV: Medium Globular Volume; AVP: Average Volume of Platelets; IDR: Red Blood Cell
 185 Distribution Index; THT: Thrombocrits; WBC: white blood cells; RBC: red blood cells.
 186

187 Table 7 shows that *O. barrelieri* extract induced significant increase (p <0.001) of aspartate
 188 aminotransferase (AST) activity two weeks after discontinuation of the extract treatment (Satellite test),
 189 in male and female rats. In female rats, urea level increased significantly (p <0.05) two weeks after
 190 stopping treatment (Satellite test). However, the significant (p <0.05) increase in triglyceride levels
 191 observed in males treated with the extract (800 mg / kg) was reversible two weeks after stopping
 192 treatment (Satellite test). Other plasma parameters (glycemia, ALT, total proteins, cholesterol,
 193 creatinine) did not show any significant variation.
 194

Table7. Effect of *Oxalis barrelieri* aqueous extract on blood biochemical parameters in rats

Parameters	Control	O.b. 200mg/kg	O.b. 400mg/kg	O.b. 800mg/kg	Satellite test	C. Sat.
Males						
Glycaemia(mg/dl)	58.40±2.50	54.40±3.11	62.40±1.50	52.40±2.14	61.20±2.44	59.00±0.84
AST (UI/l)	105.85±6.49	86.45±5.52	128.72±16.39	114.16±17.61	264.84±29.56 ***	87.07±5.03
ALT (UI/l)	62.70±6.88	64.88±7.01	68.88±3.53	66.24±1.13	55.13±6.52	51.00±3.42
Total protein(mg/dl)	96.79±5.86	94.36±5.35	80.44±5.06	91.98±4.31	80.59±4.08	84.82±2.08
Cholesterol (mg/dl)	43.30±0.32	65.91±2.67	67.39±6.73	60.73±9.05	51.33±3.42	66.07±7.12
Triglyceride (mg/dl)	76.50±8.51	78.18±7.31	87.08±10.62	121.31±10.94*	77.26±10.17	94.23±3.19
Creatinine (mg/dl)	0.51±0.04	0.63±0.03	0.58±0.06	0.53±0.03	0.69±0.02	0.61±0.05
Urea (mg/dl)	40.11±3.23	61.83±6.93	40.76±7.41	43.91±5.69	43.66±2.32	42.98±2.52
Females						
Glycaemia(mg/dl)	66.00±1.00	61.00±2.74	63.00±2.51	68.00±3.56	67.20±0.58	66.00±5.41
AST (UI/l)	98.62 ±10.43	104.51±5.66	94.36±4.38	162.76±19.92 *	217.79±21.55 ***	78.61±1.90

ALT (U/l)	47.62±7.71	42.38±3.00	51.99±2.25	39.89±3.31	45.43±7.97	39.75±8.69
Total protein (mg/dl)	84.84±6.23	83.34±3.69	72.17±7.02	72.96±1.71	92.02±2.61	87.99±3.79
Cholesterol (mg/dl)	40.44±3.99	59.06±10.58	51.44±6.46	38.97±4.09	42.78±4.45	45.42±0.78
Triglyceride (mg/dl)	57.68±5.66	74.24±4.27	55.03±5.98	64.91±11.80	77.94±9.23	66.71±8.67
Creatinine (mg/dl)	0.43±0.01	0.60±0.06	0.52±0.03	0.49±0.03	0.56±0.03	0.54±0.05
Urea (mg/dl)	31.67±4.51	33.56±2.23	33.49±2.41	29.60±3.04	59.87±8.94 *	35.87±3.61


197 n = 5 animals in each group; Values are expressed as mean ± SEM

198 * P<0,05 significant difference compared to the control group; *** P<0.001 significant difference
199 compared to the control group; Sat. C: Satellite control; O. b: *Oxalis barrelieri* aqueous extract.

200
201

202 After four weeks of *Oxalis barrelieri* extract administration, the rats of the batches receiving
203 doses of 200, 400 and 800 mg/kg presented dose-dependent vascular congestions compared to
204 control group. Observation of liver tissue, fourteen days later, showed complete repair of these
205 vascular congestions (Figure 1). Histological section analysis revealed renal tissue damage including
206 enlargement of the glomerular chamber and destruction of nephrons. This alteration is dose-
207 dependent and appears to have worsened two weeks after stopping treatment (Figure 2). The analysis
208 also showed that the said alteration is more pronounced in males than in females

209




213
214
215
216
217
218
219
220

Figure 1. Effect of *Oxalis barrelieri* aqueous extract on rat liver tissues (HE x 400)

A1 = control female; A2 = control male; B1 = 0.b 200 mg / kg (female); B2 = O.b 200 mg / kg (male);
C1 = O.b 400 mg / kg (female); C2 = O.b 400 mg / kg (male); D1 = O.b 800 mg / kg (female); D2 = O.b
800 mg / kg (male); E1 = Satellite test female; E2 = Satellite test male; F1 = satellite control female;
F2 = satellite control male; sc = sinusoidal capillary; vc = Vascular congestion; h = hepatocyte; clv =
Centro-lobular vein;

221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246



247
248
249
250
251
252
253

Figure 2. Effect of *Oxalis barrelieri* aqueous extract on rat kidney tissues (HE x 400)

A1 = control female; A2 = control male; B1 = 0.b 200 mg / kg (female); B2 = O.b 200 mg / kg (male);
C1 = O.b 400 mg / kg (female); C2 = O.b 400 mg / kg (male); D1 = O.b 800 mg / kg (female); D2 = O.b
800 mg / kg (male); E1 = Satellite test female; E2 = Satellite test male; F1 = satellite control female;
F2 = satellite control male; n = nephron; g = glomerulus; cg = glomerular capsule; d = enlargement of
the glomerular chamber.

254 **4. DISCUSSION**

255 *Oxalis barrelieri* is a medicinal plant used to treat certain pathologies such as diabetes [13]
256 and diarrhea [7,8]. In this study, the objective was to evaluate the toxic effects of this plant on
257 biological systems, particularly in the liver and kidneys.

258 The oral administration of a single dose (2000 mg / kg) of *Oxalis barrelieri* aqueous extract
259 did not cause any significant changes in either the behavior or the physical condition of these animals.
260 Noise and touch sensitivity, coat condition and nature of stool showed no significant variation (Table
261 1). No deaths were observed during 14 (fourteen) days of observation. In addition, the body weight of
262 the mice treated with *O. barrelieri* extract did not undergo any significant variation (Table 2). These
263 results suggest that the lethal dose (LD 50) of the aqueous extract of *O. barrelieri* is greater than 2000
264 mg / kg. According to OECD Guideline 423, 2001 this extract is slightly toxic [14].

265 Repeated administration for 28 days (subacute toxicity) of the *O. barrelieri* aqueous extract
266 caused no deaths in the treated animals. At all doses, *O. barrelieri* extract did not cause any significant
267 variation in animal body weight. The growth of animals treated with *O. barrelieri* extract was similar to
268 that of control group rats (Tables 3 and 4). This result suggests that *O. barrelieri* extract does not
269 significantly alter animal metabolism as well as growth hormone and cartilage [15]. The relative weight
270 of vital organs showed no significant dose-dependent variation (Table 5). However, *O. barrelieri*
271 extract at dose of 200 mg/kg increased significantly the heart relative weight. This effect was not dose-
272 dependent, it can't be attributed to the extract. In general, changes in body weight of treated animals,
273 as well as the organs weight (liver, kidneys, lungs, testicles, ovaries, spleen and heart), are indicators
274 of a substance with high toxicity [16,17]. So this extract would be slightly toxic.

275
276 Blood is one of the targets of the body most attacked by toxic substances, it provides
277 important informations on the physiology and pathologies of animals [18]. Haematological parameters
278 give informations on hematopoietic function (evaluation of cells of the myeloid lineage) and the
279 determination of the occurrence of any allergies (white blood cell studies) [19]. Blood parameter
280 analysis in rodents can provide a high predictive index (up to 91% concordance) for risk of toxicity in
281 humans [20]. Extract of *O. barrelieri* (800 mg / kg) resulted in a significant ($p < 0.05$) decrease in red
282 blood cell counts in male rats two weeks after treatment discontinuation (satellite test group). In female
283 rats, *O. barrelieri* extract (200 mg / kg) caused a significant ($p < 0.05$) non-dose-dependent increase in
284 red blood cell count (Table 6). The decrease in red blood cell count observed in male rats two weeks
285 after discontinuation showed that *O. barrelieri* extract (800 mg / kg) was transformed into a metabolite
286 that inhibited hematopoiesis. These results are close to those of *Raphia hookeri* extract [21]. These
287 toxic effects of the *O. barrelieri* aqueous extract are due to chemical composition. *O. barrelieri* extract
288 is rich in phenols, flavonoïds, tannins, alkaloids and saponins [9]. Saponins have deleterious effects
289 on red blood cells and inhibit the proliferation of erythrocytes in bone marrow [22; 23]. In addition,
290 tannins cause loss of appetite in animals [24]; alkaloids would have teratogenic effects [25].

291 Serum biochemical parameters are used to evaluate the effects of xenobiotics on liver and
292 kidney function. The liver is prone to xenobiotic-induced injury because of its central role in xenobiotic
293 metabolism, its portal location within the circulation and its anatomical and physiological structure. The
294 study of fasting blood glucose gives information on the state of functioning of the liver and pancreas.

295 However, the liver provides storage and release while the pancreas information on the availability and
296 deficiency [26]. No significant variation was observed in animals treated with the extract of *O.*
297 *barrelieri*. This result indicates that this extract does not change the functioning of the liver and
298 pancreas. Generally, analysis of the activities of some basic liver enzymes (such as ALAT and ASAT)
299 in the plasma or serum can be used to indirectly assess the integrity of tissues after being exposed to
300 certain pharmacological agents [27]. Necrosis or membrane damage releases the enzymes into
301 circulation; therefore, it can be measured in the serum. Usually, about 80% of ASAT is found in the
302 mitochondria whereas ALAT is a purely cytosolic enzyme. Therefore, ASAT appears in higher
303 concentrations in a number of tissues (liver, kidneys, heart and pancreas) and is released slowly in
304 comparison to ALAT. But since ALAT is localized primarily in the cytosol of hepatocytes, this enzyme
305 is considered a more sensitive marker of liver inflammation or damage than ASAT and within limits
306 can provide a quantitative assessment of the degree of damage sustained by the liver [28]. *O.*
307 *barrelieri* extract at 800 mg / kg resulted in a significant ($p < 0.05$) increase in ASAT activity in female
308 rats. Two weeks after stopping the administration of the extract, ASAT activity significantly ($p < 0.001$)
309 increased in both female and male rats (Table 7). This result would suggest that this extract and its
310 metabolites would cause alteration of the liver or other organs such as kidney, heart, pancreas or
311 muscles.

312 The lipid profile is an indicator of lipid metabolism in the liver [29]. The increase in serum
313 triglyceride levels is due to liver dysfunction and may cause cardiovascular problems. Triglycerides
314 increased significantly ($P < 0.01$) in male rats treated with the extract (800 mg/kg), this effect disappear
315 in the two weeks following discontinuation of therapy (table 7). This result would suggest that the *O.*
316 *barrelieri* extract might disturb hepatic lipid metabolism and cause cardiovascular problems, but this
317 effect is reversible. Estimation of total protein is one of the most widely used means of measuring
318 hepatocellular injury. Total protein measurements can reflect nutritional status and may be used to
319 screen for and help diagnose kidney disease, liver disease, and many other conditions. Low total
320 protein levels can suggest a liver disorder, a kidney disorder, or a disorder in which protein is not
321 digested or absorbed properly. High total protein levels may be seen with chronic inflammation or liver
322 infections. Total cholesterol test is used to estimate risk of developing disease (specifically cardio-
323 vascular disease) and some liver dysfunctions. Increase in the total protein and cholesterol as well
324 would have indicated hepatocyte damage [30]. There were no significant changes in serum lipid profile
325 (cholesterol) as compared to the control groups. This result suggests the absence of major
326 cardiovascular risks factors induced by *O. barrelieri* extract.

327 The kidneys are highly susceptible to toxicants for two reasons; a high volume of blood
328 flows through it and its ability to filter large amounts of toxins which can concentrate in the kidney
329 tubules. It can result in systemic toxicity causing decreased ability to excrete body wastes, inability to
330 maintain body fluid and electrolyte balance and decreased synthesis of essential hormones. Blood
331 urea nitrogen is derived in the liver protein/amino acid from dietary or tissue sources and is normally
332 excreted in the urine. In renal disease, serum urea accumulates because the rate of serum urea
333 production exceeds the rate of clearance [31]. Creatinine, on the other hand, is mostly derived from
334 endogenous sources by tissue creatine breakdown. The plasma creatinine concentrations in normal

335 individuals are usually affected by a number of factors such as the muscle mass, high protein diet and
336 catabolic state, thus serum urea concentration is often considered the more reliable renal function
337 predictor than serum creatinine [32]. There were no significant changes in the levels of serum
338 creatinine in the treated groups compared with the controls. *O. barrelieri* extract (800 mg / kg)
339 increased significantly ($p < 0.05$) the urea level that normalized in the two following treatment
340 discontinuation (Table 7). These results would suggest that the extract would have reversible
341 deleterious effects on the kidney.

342 Liver tissue analysis of animals treated with the *O. barrelieri* aqueous extract suggests the
343 presence of structural abnormalities. Hepatic vein congestion was observed in all rats given the
344 aqueous extract of *O. barrelieri* at all doses. Liver congestion could be attributed, in part, to its role in
345 biotransformation of xenobiotics [33]. However, within two weeks of stopping the extract
346 administration, this anomaly was normalized. This would suggest that hepatic vein congestion induced
347 by *O. barrelieri* aqueous extract is reversible (Figure 1). This would suggest that the liver has put in
348 place self-healing mechanisms. Kidney histology revealed the enlargement of glomerular chamber in
349 the 800 mg / kg (male rats) and satellite groups male and female rats). These observations suggest
350 that high doses of *O. barrelieri* extract would induced renal tissue damage because the rats treated
351 with the extract (200 mg / kg or 400 mg/kg) showed no structural abnormality on the renal tissue
352 (Figure 2).

353 5. CONCLUSION

354 Our study shows that the LD₅₀ of the *O. barrelieri* extract is greater than 2000 mg/kg, so
355 this extract is classified as poorly toxic substances. A study with three dose levels (200mg/kg,
356 400mg/kg and 800mg/kg) administered daily to the animals, for 28 days period, showed some
357 abnormalities of the hematological and serum parameters. In addition, the hepatic vascular congestion
358 observed was reversible whereas the dilation of the renal glomerular chamber is not. These effects
359 were more pronounced at the 800 mg / kg extract dose. Further investigations need to be done for the
360 complete elucidation of the safety profile of *O. barrelieri*.

361 6. CONFLICT OF INTERESTS

362 The authors declare that there is no conflict of interests regarding the publication of this paper.

363

364 7. REFERENCES

- 365 1. Guzman CC, Siemonsma JS. Plant Resources of South-East Asia, Spices, Backhuys Publishers,
366 Leiden.1999; 13:161-162.
- 367 2. Bach D, Mascre M, Dey SG. Cours de botanique générale. Tome II, London, 1967 ;pp : 353-365.
368 French.
- 369 3. Otiobo AEN, Tchuenguem FFN, Djieto-Lordon C. Activité de butinage et de pollinisation de *Apis*
370 *mellifera adansonii* Latreille (Hymenoptera: Apidae) sur les fleurs d'*Oxalis barrelieri* (Oxalidaceae)
371 à Yaoundé (Cameroun). *Entomologie Faunistique – Faunistic Entomology* 2015; 68: 101-108.
372 French.
- 373 374 4. Smith AC. (1985) *Flora vitensis nova: A new flora of Fiji*. National tropical botanical garden Lawai
375 Kauai Hawaii 3 :758

- 376 5. Cavin A, Dyatmyko W, Hostettmann K. Screening of Indonesian plants for antifungal and free radical
377 scavenging activities. *Pharmaceutical biology*.1999; 37(4): 260-268.
- 378 6. Enoch KP, Mohd RS, Mohd NH, Mohamad TH, Mohd ZAB. Hypoglycemic and antidiabetic effect of
379 aqueous and ethanol extract of *Oxalis barrelieri* in streptozotocin-induced diabetes rat models. Abstract
380 of the 21st Scientific Meeting of MSPP. *Malaysian Journal of Pharmaceutical Sciences*.2007; 5(1), 23.
- 381 7. Fokam TMA, Kamgang R, Noubissi PA, Essame OJL. Activity of *Oxalis barrelieri* aqueous extract on
382 rat secretory diarrhea and intestine transit. *Journal of Applied pharmaceutical science*. 2015; 1:058-
383 062.
- 384 8. Fokam TMA, Noubissi PA, Fankem GO, Kamgang R. Effects of *Oxalis barrelieri* L.(Oxalidaceae)
385 aqueous extract on diarrhea induced by *Shigella dysenteriae* type 1 in rats. *Health Sci Rep*.
386 2017;e20. <https://doi.org/10.1002/hsr2.20>
- 387 9. Nurraihana H, Norfarizan-Hanoon NA, Hasmah A, Wan RWI. Phytochemical and Antioxidant Potential
388 of Four Traditional Malaysian Medicinal Plants. *Journal Tropical Resources Sustainable Science*. 2017;
389 5: 9-14
- 390 10. OCDE (Organization for Economic Co-operation and Development) 423, Toxicité orale aiguë, méthode
391 de la dose prédéterminée. Ligne directrice de l'OCDE pour les essais de produits chimiques. 2001; 1-
392 15. French.
- 393 11. Thanabhorn S, Jaijoy K, Thamaree S, Ingkaninan K, Panthong A. Acute and subacute toxicity study of
394 the ethanol extract from *Lonicera japonica* Thunb. *Journal of Ethnopharmacology*. 2006; 107: 370-373.
- 395 12. Tan P, Mezui C, Enow-Orock G, Njifutie N, Dimo T, Bitolog P. Teratogenic effects, acute and sub
396 chronic toxicity of the leaf aqueous extract of *Ocimum suave* Wild (Lamiaceae) in rats. *Journal of*
397 *Ethnopharmacology*. 2008; 115: 232–237.
- 398 13. Enoch KP, Sulaiman MR, Somchit MN, Hidayat MT, Md Zuki AB. Effets hypoglycémique et
399 antidiabétique d'une solution aqueuse et d'éthanol de l'extrait de *Oxalis barrelieri* dans les modèles de
400 rats diabétiques induits par la streptozotocine. Actes de la 21^e réunion scientifique de la société
401 malaysienne de pharmacologie et de physiologie.2006 ; 42. French.
- 402 14. OCDE 423. Toxicité orale aiguë, méthode de la dose prédéterminée. Ligne directrice de l'O.C.D.E pour
403 les essais de produits chimiques.2001 ; 1-15. French.
- 404 15. Mezui C, Longo F, Nkenfou C, Sando Z, Ndeme E, Tan PV. Evaluation of acute and subacute toxicity
405 of stem barks aqueous extract of *Anthocleista schweinfurthii* (Loganiaceae). *World Journal of*
406 *Pharmacy and Pharmaceutical Sciences*. 2015; 4(03): 197-208
- 407 16. Raza M, Al-Shabanah O, El-Hadiyah A. Effect of prolonged vigabatrin treatment on hematological and
408 biochemical parameters in plasma, liver and kidney of Swiss albino mice. *Scientia Pharmaceutica*.
409 2002; 70: 135-145.
- 410 17. Tarkang PA, Agbor GA, Tchamgoue DA, Tchokouaha LRY, Kemeta D, Mengue NYS. Acute and
411 Chronic Toxicity Studies of the aqueous and ethanol leaf extracts of *Carica papaya* Linn in Wistar rats.
412 *Journal of Natural Product and Plant Resources*. 2012; 2(5): 617-627.
- 413 18. Adeneye AA, Ajagbonna OP, Adeleke TI, Bello SO. Preliminary toxicity and phytochemical studies of
414 the stem bark of aqueous extract of *Musanga cecropioides* in rats. *Journal of Ethnopharmacology*.
415 2006; 105: 374-379.

- 416 19. Sherwood. Physiologie humaines: 2ème édition. De Boeck, Paris. 2006; 452-462. French.
- 417 20. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G,
418 Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A. Concordance of toxicity of
419 pharmaceuticals in humans and in animals. *Regulatory Toxicology and Pharmacology*. 2000;
420 32:56-67.
- 421 21. Mbaka GO, Ogbonnia SO, Olubamido TO, Awopetu PI, Ota DA. Evaluation of Acute and Sub-
422 chronic Toxicities of Aqueous Ethanol Root Extract of *Raphia hookeri* (Palmaceae) on Swiss
423 Albino Rats. *British Journal of Pharmacology and Toxicology*.2014 ; 5(4): 129-135.
- 424 22. Igweh AC, Onabanjo A O. Chemotherapeutic effects of *Annona senegalensis* on *Trypanosoma*
425 *brucei brucei*. *Annals of Tropical Medicine and Parasitology*.1989; 83:527-534.
- 426 23. Araee M, Norouzi M, Habibi G, Sheikhvatan M. Toxicity of *Trigonella foenum-graecum* L.
427 (fenugreek) in bone marrow cell proliferation in rat. *Pakistan Journal of Pharmaceutical*
428 *Sciences*.2009 ; 22: 126–130.
- 429 24. Usman MM, Sule MS; Gwarzo MY. Toxicological studies of aqueous root extract of *Euphorbia*
430 *lateriflora* (Schum and Thonn) in rats. *Journal of Medicinal Plants Studies*. 2014; 2(2): 58-62
- 431 25. Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic *Veratrum* alkaloid cyclopamine
432 inhibits Sonic hedgehog signal transduction. *Development*. 1998; 125: 3553–3562.
- 433 26. Ganong W. Medical physiology. Edition Masson, Paris: 1999; 448-475.
- 434 27. Al-Hashem F. Camel's milk protects against aluminum chloride-induced toxicity in the liver and kidney
435 of white albino rats. *American Journal Biochemistry and Biotechnology*. 2009; 5: 98-108.
- 436 28. Hilaly JE, Israili ZH, Lyoussi B. Acute and chronic toxicological studies of *Ajugaiva* in experimental
437 animals. *Journal of Ethnopharmacology*. 2004; 91(1): 43-50.
- 438 29. Janardan KR, Rao MS. Lipid Metabolism and Liver Inflammation. Fatty liver disease and fatty acid
439 oxidation. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2006; 290: 852-
440 858.
- 441 30. Aniagu SO, Nwinyi FC, Akumka DD, Ajoku GA, Dzarma S, Izebe KS, Ditse M, Nwaneri PEC,
442 Wambebe C, Gamaniel K. Toxicity studies in rats fed nature cure bitters. *African Journal of*
443 *Biotechnology*. 2002; 4(1):72-78.
- 444 31. Mayne P, Mayne PD. Clinical chemistry in diagnosis and treatment. A Hodder Arnold Publication.
445 6th Ed. London; 1994.
- 446 32. Hilaly JE, Israili ZH, Lyoussi B. Acute and chronic toxicological studies of *Ajugaiva* in experimental
447 animals. *Journal of Ethnopharmacology*. 2004; 91(1):43-50.
- 448 33. Bulus T, Atawodi SE, Mamman M. Acute toxicity effect of the aqueous extract of *Terminalia*
449 *avicennioides* on white albino rats. *Science World Journal*. 2011; 6 (2):1- 4